Literature DB >> 17666079

Hypothermia treatment potentiates ERK1/2 activation after traumatic brain injury.

Coleen M Atkins1, Anthony A Oliva, Ofelia F Alonso, Shaoyi Chen, Helen M Bramlett, Bing-Ren Hu, W Dalton Dietrich.   

Abstract

Traumatic brain injury (TBI) results in significant hippocampal pathology and hippocampal-dependent memory loss, both of which are alleviated by hypothermia treatment. To elucidate the molecular mechanisms regulated by hypothermia after TBI, rats underwent moderate parasagittal fluid-percussion brain injury. Brain temperature was maintained at normothermic or hypothermic temperatures for 30 min prior and up to 4 h after TBI. The ipsilateral hippocampus was assayed with Western blotting. We found that hypothermia potentiated extracellular signal-regulated kinase 1/2 (ERK1/2) activation and its downstream effectors, p90 ribosomal S6 kinase (p90RSK) and the transcription factor cAMP response element-binding protein. Phosphorylation of another p90RSK substrate, Bad, also increased with hypothermia after TBI. ERK1/2 regulates mRNA translation through phosphorylation of mitogen-activated protein kinase-interacting kinase 1 (Mnk1) and the translation factor eukaryotic initiation factor 4E (eIF4E). Hypothermia also potentiated the phosphorylation of both Mnk1 and eIF4E. Augmentation of ERK1/2 activation and its downstream signalling components may be one molecular mechanism that hypothermia treatment elicits to improve functional outcome after TBI.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666079     DOI: 10.1111/j.1460-9568.2007.05720.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  26 in total

Review 1.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

2.  Post-traumatic seizure susceptibility is attenuated by hypothermia therapy.

Authors:  Coleen M Atkins; Jessie S Truettner; George Lotocki; Juliana Sanchez-Molano; Yuan Kang; Ofelia F Alonso; Thomas J Sick; W Dalton Dietrich; Helen M Bramlett
Journal:  Eur J Neurosci       Date:  2010-10-29       Impact factor: 3.386

Review 3.  Use of hypothermia in the intensive care unit.

Authors:  Jesse J Corry
Journal:  World J Crit Care Med       Date:  2012-08-04

4.  Phosphodiesterase isoform-specific expression induced by traumatic brain injury.

Authors:  Anthony A Oliva; Yuan Kang; Concepcion Furones; Ofelia F Alonso; Olga Bruno; W Dalton Dietrich; Coleen M Atkins
Journal:  J Neurochem       Date:  2012-11-01       Impact factor: 5.372

Review 5.  Hypothermic treatment for acute spinal cord injury.

Authors:  W Dalton Dietrich; Allan D Levi; Michael Wang; Barth A Green
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

6.  Posttraumatic hypothermia increases doublecortin expressing neurons in the dentate gyrus after traumatic brain injury in the rat.

Authors:  Amade Bregy; Ryan Nixon; George Lotocki; Ofelia F Alonso; Coleen M Atkins; Pantelis Tsoulfas; Helen M Bramlett; W Dalton Dietrich
Journal:  Exp Neurol       Date:  2011-12-14       Impact factor: 5.330

7.  Emergence of cognitive deficits after mild traumatic brain injury due to hyperthermia.

Authors:  David J Titus; Concepcion Furones; Coleen M Atkins; W Dalton Dietrich
Journal:  Exp Neurol       Date:  2014-10-29       Impact factor: 5.330

8.  Decoding hippocampal signaling deficits after traumatic brain injury.

Authors:  Coleen M Atkins
Journal:  Transl Stroke Res       Date:  2011-12       Impact factor: 6.829

Review 9.  Therapeutic hypothermia and targeted temperature management in traumatic brain injury: Clinical challenges for successful translation.

Authors:  W Dalton Dietrich; Helen M Bramlett
Journal:  Brain Res       Date:  2015-12-30       Impact factor: 3.252

Review 10.  Contemporary management of traumatic intracranial hypertension: is there a role for therapeutic hypothermia?

Authors:  Matthew Schreckinger; Donald W Marion
Journal:  Neurocrit Care       Date:  2009-12       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.